Research Publications

Hagen M, Müller F, Wirsching A, Kharboutli S, Spoerl S, Düsing C, Krickau T, Metzler M, Völkl S, Aigner M, Kretschmann S, Vasova I, Saake M, Schliep S, Kubacki T, Hunzelmann N, Bucci L, Taubmann J, Bergmann C, Györfi AH, Dietrich S, Distler JHW, Grieshaber-Bouyer R, Mackensen A, Schett G. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus - Authors' reply. Lancet Rheumatol. 2025 Oct;7(10):e667-e669. doi: 10.1016/S2665-9913(25)00222-X. Epub 2025 Aug 12.PMID: 40816306

Chen Y, Gong Y, Shi M, Zhu H, Tang Y, Huang D, Wang W, Shi C, Xia X, Zhang Y, Liu J, Huang J, Liu M, Chen H, Ma Y, Wang Z, Wang L, Tu W, Zhao Y, Lin J, Jin L, Distler JH, Wu W, Wang J, Shi X. miR-3606-3p alleviates skin fibrosis by integratively suppressing the integrin/FAK, p-AKT/p-ERK, and TGF-β signaling cascades. J Adv Res. 2025 Sep;75:271-290. doi: 10.1016/j.jare.2024.11.027. Epub 2024 Nov 20.PMID: 39571732

Trinh-Minh T, Tran-Manh C, Györfi AH, Dickel N, Liebel C, Zhou X, Wang J, Kunz M, Arozenius H, Pettersson L, Lindgren S, Wenglén C, Distler JHW. Antifibrotic effects of specific targeting of the 5-hydroxytryptamine 2B receptor (5-HT2BR) in murine models and ex vivo models of scleroderma skin. Arthritis Rheumatol. 2025 Aug;77(8):1063-1076. doi: 10.1002/art.43151. Epub 2025 Apr 17.PMID: 40064593 

Kaufman J, Nabozny G, Tran-Manh C, Liebel C, Zhou X, Daley LA, Wang CT, Ebenezer DL, Delic D, Wohnhaas CT, Trinh-Minh T, Distler JHW. Avenciguat: a novel soluble guanylate cyclase activator that affects multiple cell types to inhibit IFN-1 signalling and fibrosis. Rheumatology (Oxford). 2025 Aug 1;64(8):4738-4743. doi: 10.1093/rheumatology/keaf109.PMID: 39985455